aTyr Pharma is a San Diego-based biopharmaceutical company specializing in the development of innovative therapies for fibrosis and inflammation. With a focus on translating tRNA synthetase biology, the company aims to address unmet medical needs in conditions such as pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Through their extensive research and development pipeline, aTyr Pharma is dedicated to discovering and advancing novel drug candidates, including Efzofitimod and ATYR2810, with the goal of providing effective treatment options for patients. With a strong emphasis on scientific expertise and a commitment to improving patient outcomes, aTyr Pharma is at the forefront of developing transformative therapies in the field of biotechnology.
Generated from the website